Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer clinical trial (NCT00954876). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination of capecitabine and cetuximab compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer clinical trial (NCT00954876). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer clinical trial (NCT00954876). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer clinical trial (NCT00954876). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the treatment cycles?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer clinical trial (NCT00954876). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any specific tests or procedures I will need to undergo as part of this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer clinical trial (NCT00954876). Contact the study team or your healthcare provider for specific answers.

What this study is about